Clotrimazole vs. Mycelex® in Patients With Human Insufficiency Virus (HIV) Infection for the Treatment of Oropharyngeal Candidiasis

Inclusion Criteria: * Documented HIV positive status * Clinical examination of oropharynx is consistent with diagnosis of oral Candidiasis (such as creamy, white, curdlike patches or erythematous lesions on mucosal surfaces) * Findings on direct microscopic examination (Gram Stain or potassium hydroxide smear) consistent with Candida species or positive fungal culture for Candida species, with culture obtained in the 2 days preceding initiation of therapy with the study drug * Male or female patients ≥ 18 years * For women of childbearing potential: negative blood or urine pregnancy test and agreement to use adequate contraception (investigator's discretion) while on study drug * Mental status allows comprehension of instructions for troche administration * Written informed consent Exclusion Criteria: * Sings of symptoms suggestive of esophageal Candidiasis (such as dysphagia or odynophagia) unless the results of an endoscopic evaluation of the esophagus are negative * Presence of perioral lesions only * Use of other antifungal agents within 5 days of enrollment to the study * Pregnant or lactating women * History of hypersensitivity to imidazole or azole compounds * Patient unwilling or unable to be followed at the study center for the duration of the study (3 weeks) * Patients has received an investigational drug in the last 30 days * Treatment with another investigational drug is planned within the next 3 weeks